Cutting edge: CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice

Journal of Immunology

Volumn 161, Issue 9, 1998, Pages 4463-4466

  McCluskie, Michael J ^a,b   Davis, Heather L ^a,b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA TOXIN; DNA; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; OLIGODEOXYNUCLEOTIDE; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; IMMUNOGLOBULIN G; OLIGONUCLEOTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CPG ISLAND; FEMALE; HUMORAL IMMUNITY; INTRANASAL DRUG ADMINISTRATION; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BLOOD; CHEMISTRY; COMPARATIVE STUDY; DRUG POTENTIATION; EVALUATION; FECES; HEPATITIS B; IMMUNOLOGY; LUNG; LUNG LAVAGE; NOSE MUCOSA; TH1 CELL; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; CHOLERA TOXIN; CPG ISLANDS; DRUG SYNERGISM; EVALUATION STUDIES; FECES; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; IMMUNOGLOBULIN G; LUNG; MICE; MICE, INBRED BALB C; NASAL MUCOSA; OLIGONUCLEOTIDES; TH1 CELLS; TH2 CELLS;

EID: 0032209286     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Haneberg, B., D. Kendall, H. M. Amerongen, F. M. Apter, J.-P. Kraehenbuhl, and M. R. Neutra. 1994. Induction of specific immunoglobulin A in the small intestine, colon-rectum, and vagina measured by a new method for collection of secretions from local mucosal surfaces. Infect. Immun. 62:15.
2. Gallichan, W. S., and K. L. Rosenthal. 1995. Specific secretory immune responses in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus. Vaccine 13:1589.
3. Rappuoli, R., G. Douce, G. Dougan, and M. Pizza. 1995. Genetic detoxification of bacterial toxins: a new approach to vaccine development. Int. Arch. Allergy Immunol. 108:327.
4. Fontana, M. R., R. Manetti, V. Giannelli, C. Magagnoli, A. Marchini, R. Olivieri, M. Domenighini, R. Rappuoli, and M. Pizza. 1995. Construction of nontoxic derivatives of cholera toxin and characterization of the immunological response against the A subunit. Infect. Immun. 63:2356.
5. Krieg, A. M., A.-K. Yi, S. Matson, T. J. Waldschmidt, G. A. Bishop, R. Teasdale, G. Koretzky, and D. Klinman. 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374:546.
6. Yi, A. K., P. Hornbeck, D. E. Lafrenz, and A. M. Krieg. 1996. CpG DNA rescue of murine B lymphoma cells from anti-IgM-induced growth arrest and programmed cell death is associated with increased expression of c-myc and bcl-xL. J. Immunol. 157:4918.
7. Klinman, D., A.-K. Yi, S. L. Beaucage, J. Conover, and A. M. Krieg. 1996. CpG motifs expressed by bacterial DNA rapidly induce lymphocytes to secrete IL-6, IL-12, and IFN-γ. Proc. Natl. Acad. Sci. USA 93:2879.
8. Halpern, M. D., Kurlander, R. J., and D. S. Pisetsky. 1996. Bacterial DNA induces murine interferon-γ production by stimulation of interleukin-12 and tumor necrosis factor-α. Cell. Immunol. 167:72.
9. Yamamoto, S., T. Yamamoto, S. Shimada, E. Kuramoto, O. Yano, T. Kataoka, and T. Tokunaga. 1992. DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. Microbiol. Immunol. 36:983.
10. Ballas, Z. K., W. L. Rasmussen, and A. M. Krieg. 1996. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J. Immunol. 157:1840.
11. Roman, M., E. Martin-Orozco, J. S. Goodman, M. D. Nguyen, Y. Sato, A. Ronaghy, R. S. Kornbluth, D. D. Richman, D. A. Carson, and E. Raz. 1997. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat. Med. 3:849.
12. Davis, H. L., R. Weeratna, T. J. Waldschmidt, J. Schorr, and A. M. Krieg. 1998. CpG DNA is a potent adjuvant in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 160:870.
13. Chu, R. S., O. S. Targoni, A. M. Krieg, P. V. Lehmann, and C. V. Harding. 1997. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. 186:1623.
14. Lipford, G. B., T. Sparwasser, M. Bauer, S. Zimmermann, E. S. Koch, K. Heeg, and H. Wagner. 1997. Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines. Eur. J. Immunol. 27:3420.
15. Weiner, G. J., H. M. Liu, J. E. Wooldridge, C. E. Dahle, and A. M. Krieg. 1997. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc. Natl. Acad. Sci. USA 94:10833.
16. Sun S., H. Kishimoto, and J. Sprent. 1998. DNA as an adjuvant: capacity of insect DNA and synthetic oligodeoxynucleotides to augment T cell responses to specific antigen. J. Exp. Med. 187:1145.
17. Moldoveanu Z., L. Love-Homan, W. Q. Huang, and A. M. Krieg. 1998. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 16:1216.
18. McCluskie M. J., Y. Chu, J.-L. Xia, J. Jessee, G. Gebeyehu, and H. L. Davis. Direct gene transfer to the respiratory tract of mice with pure plasmid and lipid-formulated DNA. Antisense Nucleic Acid Drug Dev. In press.
19. Lamm, M. E., M. B. Mazanec, J. G. Nedrud, and C. S. Kaetzel. 1992. Mechanisms of IgA-mediated mucosal defense. Vaccine Res. 1:169.
20. McGhee, J. R., J. Mestecky, M. T. Dertzbaugh, J. H. Eldridge, M. Hirasawa, and H. Kiyono. 1992. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine 10:75.
21. Kramer, D., R. M. Sutherland, S. Bao, and A. J. Husband. 1995. Cytokine-mediated effects in mucosal immunity. Immunol. Cell Biol. 73:389.
22. Takahashi, I., M. Marinaro, H. Kiyono, R. J. Jackson, I. Nakagawa, K. Fujihashi, S. Hamada, J. D. Clements, K. L. Bost, and J. R. McGhee. 1996. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J. Infect. Dis. 173:627.
23. Munoz, E., A. M. Zubiaga, M. Merrow, N. P. Sauter, and B. T. Huber. 1990. Cholera toxin discriminates between T helper 1 and 2 cells in T cell receptor-mediated activation: role of cAMP in T cell proliferation. J. Exp. Med. 172:95.
24. Ramsay, A. J., A. J. Husband, I. A. Ramshaw, S. Bao, K. I. Matthaei, G. Koehler, and M. Kopf. 1994. The role of interleukin-6 in mucosal IgA antibody responses in vivo. Science 264:561.
25. Marinaro, M., P. N. Boyaka, F. D. Finkelman, H. Kiyono, R. J. Jackson, E. Jirillo, and J. R. McGhee. 1997. Oral but not parenteral interleukin (IL)-12 redirects T helper 2 (Th2)-type responses to an oral vaccine without altering mucosal IgA responses. J. Exp. Med. 185:415.
26. Marinaro, M., P. N. Boyaka, R. J. Jackson, F. D. Finkelman, H. Kiyono, and J. R. McGhee. 1996. Interleukin-12 alters helper T-cell subsets and antibody profiles induced by the mucosal adjuvant cholera toxin. Ann. N. Y. Acad. Sci. 795:361.
27. Kay, A. B. 1996. TH2-type cytokines in asthma. Ann. N. Y. Acad. Sci. 796:1.
28. Hogg, J. C. 1997. The pathology of asthma. APMIS 105:735.
29. Kline, J. N., T. J. Waldschmidt, T. R. Businga, J. E. Lemish, J. V. Weinstock, P. S. Thorne, and A. M. Krieg. 1998. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J. Immunol. 160:2555.
30. Jertborn, M., A. M. Svennerholm, and J. Holmgren. 1992. Safety and immunogenicity of an oral recombinant cholera B subunit-whole cell vaccine in Swedish volunteers. Vaccine 10:130.
31. Spangler, B. D. 1992. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol. Rev. 56:622.
32. Elson, C. O. 1992. The role of cholera toxin in induction of IgA responses. Vacc. Res. 1:227.